Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
Inge M Van der SluisLeiah J BrigithaMarta FioccoHester A de Groot-KrusemanMarc BieringsCor van den BosValerie de HaasPeter M HoogerbruggeWim J E TissingMargreet A VeeningRob PietersPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
A continuous dosing schedule of PEGasp is an effective approach to prevent antibody formation and inactivating hypersensitivity reactions. The continuous PEGasp schedule did not increase toxicity and did not affect the efficacy of the therapy.